» Articles » PMID: 26910370

Linneg Sca-1high CD49fhigh Prostate Cancer Cells Derived from the Hi-Myc Mouse Model Are Tumor-initiating Cells with Basal-epithelial Characteristics and Differentiation Potential in Vitro and in Vivo

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Feb 25
PMID 26910370
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

A cell line was established from ventral prostate (VP) tumors of one-year-old Hi-Myc mice. These cells, called HMVP2 cells, are LinnegSca-1highCD49fhigh with high CD44 and CD29 expression and express CK14, Sca-1 and CD49f (but not CK8), suggesting basal-epithelial characteristics. Furthermore, HMVP2 cells form spheroids and both the cells and spheroids produce tumors in syngeneic mice. After four days of culture, HMVP2 spheroids underwent a gradual transition from LinnegSca-1highCD49fhigh expression to LinnegSca-1lowCD49flow while a subpopulation of the cells retained the original LinnegSca-1highCD49fhigh expression pattern. Additional cell subpopulations expressing Lin positive markers were also present suggesting further differentiation of HMVP2 spheroids. Two additional highly tumorigenic cell lines (HMVP2A1 and HMVP2A2) were isolated from HMVP2 cells after subsequent tumor formation in FVB/N mice. Concurrently, we also established cell lines from the VP of 6 months old Hi-Myc mice (named as HMVP1) and FVB/N mice (called NMVP) having less aggressive growth properties compared to the other three cell lines. AR expression was reduced in HMVP2 cells compared to NMVP and HMVP1 cells and almost absent in HMVP2A1 and HMVP2A2 cells. These cell lines will provide valuable tools for further mechanistic studies as well as preclinical studies to evaluate preventive and/or therapeutic agents for prostate cancer.

Citing Articles

Novel two-tiered screening approach identifies synergistic combinations of natural compounds for prostate cancer prevention and treatment.

Friedman C, Saha A, Hackman G, Lu X, Lodi A, Tiziani S Mol Carcinog. 2024; 63(4):589-600.

PMID: 38197430 PMC: 10939931. DOI: 10.1002/mc.23674.


Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition.

Saha A, Zhao S, Kindall A, Wilder C, Friedman C, Clark R J Exp Clin Cancer Res. 2023; 42(1):119.

PMID: 37170264 PMC: 10173527. DOI: 10.1186/s13046-023-02677-2.


Stromal androgen signaling acts as tumor niches to drive prostatic basal epithelial progenitor-initiated oncogenesis.

Hiroto A, Kim W, Pineda A, He Y, Lee D, Le V Nat Commun. 2022; 13(1):6552.

PMID: 36323713 PMC: 9630272. DOI: 10.1038/s41467-022-34282-w.


CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells.

Ahn S, Saha A, Clark R, Kolonin M, DiGiovanni J Oncogene. 2022; 41(41):4633-4644.

PMID: 36088505 DOI: 10.1038/s41388-022-02466-9.


Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes.

Kim W, Olson A, Mi J, Wang J, Lee D, Le V Nat Commun. 2022; 13(1):4364.

PMID: 35902588 PMC: 9334353. DOI: 10.1038/s41467-022-32119-0.


References
1.
Sharma P, Schreiber-Agus N . Mouse models of prostate cancer. Oncogene. 1999; 18(38):5349-55. DOI: 10.1038/sj.onc.1203037. View

2.
Williams A, Higgins J, Zhao H, Ljunberg B, Brooks J . CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol. 2009; 9:9. PMC: 2788570. DOI: 10.1186/1472-6890-9-9. View

3.
GROSSMANN M, Huang H, Tindall D . Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001; 93(22):1687-97. DOI: 10.1093/jnci/93.22.1687. View

4.
Shen M, Abate-Shen C . Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24(18):1967-2000. PMC: 2939361. DOI: 10.1101/gad.1965810. View

5.
Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini M . Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells. 2012; 30(6):1076-86. DOI: 10.1002/stem.1087. View